-
公开(公告)号：US11229606B2
公开(公告)日：2022-01-25
申请号：US16609397
申请日：2019-06-18
IPC分类号： A61K9/28 , A61K31/4425 , A61K9/50
摘要： Extended release pyridostigmine dosage forms, suitable for maintaining stable plasma concentrations with reduced or minimized initial burst release/dose dumping of pyridostigmine, are provided. The dosage forms include matrix tablets, gastroretentive tablets, and pellets, the latter being suitable for dosing in capsules, tablets, and sachets, as well as for sprinkling on foodstuffs. The disclosure also provides methods for improving patient compliance by administering once-a-day extended release pyridostigmine bromide dosage forms that provide a superior controlled drug release.
-
公开(公告)号：US10987311B2
公开(公告)日：2021-04-27
申请号：US16445110
申请日：2019-06-18
IPC分类号： A61K9/20 , A61K31/4425 , A61K9/28
摘要： Extended release pyridostigmine dosage forms, suitable for maintaining stable plasma concentrations with reduced or minimized initial burst release/dose dumping of pyridostigmine, are provided. The dosage forms include matrix tablets, gastroretentive tablets, and pellets, the latter being suitable for dosing in capsules, tablets, and sachets, as well as for sprinkling on foodstuffs. The disclosure also provides methods for improving patient compliance by administering once-a-day extended release pyridostigmine bromide dosage forms that provide a superior controlled drug release.
-
公开(公告)号：US20210069117A1
公开(公告)日：2021-03-11
申请号：US16609397
申请日：2019-06-18
IPC分类号： A61K9/28 , A61K31/4425 , A61K9/50
摘要： Extended release pyridostigmine dosage forms, suitable for maintaining stable plasma concentrations with reduced or minimized initial burst release/dose dumping of pyridostigmine, are provided. The dosage forms include matrix tablets, gastroretentive tablets, and pellets, the latter being suitable for dosing in capsules, tablets, and sachets, as well as for sprinkling on foodstuffs. The disclosure also provides methods for improving patient compliance by administering once-a-day extended release pyridostigmine bromide dosage forms that provide a superior controlled drug release.
-
公开(公告)号：US20200261372A1
公开(公告)日：2020-08-20
申请号：US16864638
申请日：2020-05-01
IPC分类号： A61K9/28 , A61K9/20 , A61K31/4453
摘要： The present disclosure provides extended release trihexyphenidyl compositions suitable for once- or twice-daily administration. The compositions comprise a core comprising organic acid that is coated with at least one drug layer comprising trihexyphenidyl hydrochloride, and a functional coat over the drug-layered core. The extended release compositions of the disclosure provide reduced Cmax, a Cmin:Cmax ratio of ≥0.4, and extended release, while maintaining therapeutically effective concentration, of trihexyphenidyl for at least about 16 hours. The compositions of the disclosure improve solubility of trihexyphenidyl hydrochloride, at a pH of greater than or equal to 5, to maintain its minimum effective concentration at such pH.
-
公开(公告)号：US10744093B2
公开(公告)日：2020-08-18
申请号：US16774899
申请日：2020-01-28
IPC分类号： A61K9/20 , A61K31/4425
摘要： Extended release pyridostigmine dosage forms, suitable for maintaining stable plasma concentrations with reduced or minimized initial burst release/dose dumping of pyridostigmine, are provided. The dosage forms include matrix tablets, gastroretentive tablets, and pellets, the latter being suitable for dosing in capsules, tablets, and sachets, as well as for sprinkling on foodstuffs. The disclosure also provides methods for improving patient compliance by administering once-a-day extended release pyridostigmine bromide dosage forms that provide a superior controlled drug release.
-
公开(公告)号：US20200261359A1
公开(公告)日：2020-08-20
申请号：US16868056
申请日：2020-05-06
发明人： Kanji Meghpara , Jaydeep Vaghashiya , Navnit H. Shah , Dipen Desai , Wantanee Phuapradit , Harpreet Kaur Sandhu , Siva Ram Kiran Vaka , Namdev B. Shelke , Ashish Chatterji
IPC分类号： A61K9/00 , A61K31/4412 , A61K31/421 , A61K31/403 , A61K31/195 , A61K9/28
摘要： The present disclosure is directed to floating gastroretentive dosage forms with prolonged gastric residence time. The disclosure also provides rapidly expanding sustained release or combined immediate release and sustained release formulations comprising drugs that require targeted release in the proximal gastrointestinal tract for maximum therapeutic benefit. The rapidly expanding floating gastroretentive dosage forms comprise a permeable elastic membrane providing desired characteristics for drug release and mechanical strength to maintain tablet integrity.
-
公开(公告)号：US10588863B2
公开(公告)日：2020-03-17
申请号：US16556092
申请日：2019-08-29
IPC分类号： A61K9/20 , A61K31/4425
摘要： Extended release pyridostigmine dosage forms, suitable for maintaining stable plasma concentrations with reduced or minimized initial burst release/dose dumping of pyridostigmine, are provided. The dosage forms include matrix tablets, gastroretentive tablets, and pellets, the latter being suitable for dosing in capsules, tablets, and sachets, as well as for sprinkling on foodstuffs. The disclosure also provides methods for improving patient compliance by administering once-a-day extended release pyridostigmine bromide dosage forms that provide a superior controlled drug release.
-
公开(公告)号：US10857098B2
公开(公告)日：2020-12-08
申请号：US16868056
申请日：2020-05-06
发明人： Kanji Meghpara , Jaydeep Vaghashiya , Navnit H. Shah , Dipen Desai , Wantanee Phuapradit , Harpreet Kaur Sandhu , Siva Ram Kiran Vaka , Namdev B. Shelke , Ashish Chatterji
IPC分类号： A61K9/00 , A61K9/28 , A61K31/195 , A61K31/403 , A61K31/421 , A61K31/4412
摘要： The present disclosure is directed to floating gastroretentive dosage forms with prolonged gastric residence time. The disclosure also provides rapidly expanding sustained release or combined immediate release and sustained release formulations comprising drugs that require targeted release in the proximal gastrointestinal tract for maximum therapeutic benefit. The rapidly expanding floating gastroretentive dosage forms comprise a permeable elastic membrane providing desired characteristics for drug release and mechanical strength to maintain tablet integrity.
-
公开(公告)号：US20200163889A1
公开(公告)日：2020-05-28
申请号：US16774899
申请日：2020-01-28
IPC分类号： A61K9/20 , A61K31/4425
摘要： Extended release pyridostigmine dosage forms, suitable for maintaining stable plasma concentrations with reduced or minimized initial burst release/dose dumping of pyridostigmine, are provided. The dosage forms include matrix tablets, gastroretentive tablets, and pellets, the latter being suitable for dosing in capsules, tablets, and sachets, as well as for sprinkling on foodstuffs. The disclosure also provides methods for improving patient compliance by administering once-a-day extended release pyridostigmine bromide dosage forms that provide a superior controlled drug release.
-
公开(公告)号：US20210330657A1
公开(公告)日：2021-10-28
申请号：US17272481
申请日：2019-09-19
IPC分类号： A61K31/4453 , A61K9/50 , A61K9/00 , A61K47/12
摘要： The present disclosure provides extended release trihexyphenidyl compositions suitable for once- or twice-daily administration. The compositions comprise a core comprising organic acid that is coated with at least one drug layer comprising trihexyphenidyl hydrochloride, and a functional coat over the drug-layered core. The extended release compositions of the disclosure provide extended release of trihexyphenidyl hydrochloride, with reduced Cmax, and a Cmin:Cmax ratio of ≥0.4, while maintaining a therapeutically effective concentration for a period of at least about 16 hours. The compositions of the disclosure improve solubility of trihexyphenidyl hydrochloride, at a pH of greater than or equal to 5, to maintain its minimum effective concentration at such pH. In certain embodiments, the compositions of the disclosure comprise an IR drug layer to provide extended release with a minimal lag time, while maintaining a therapeutically effective concentration of trihexyphenidyl hydrochloride for a period of at least about 16 hours.
-
-
-
-
-
-
-
-
-
搜索结果
11 条记录 (耗时 0.013 秒)
